Selected topics: cardiology commentaryElectrocardiographic manifestations: Digitalis toxicity1
Introduction
The objective of this article is to review the electrocardiographic manifestations of digitalis toxicity, particularly as they relate to the pathophysiology and management of this potentially lethal poisoning. Despite the introduction of new classes of drugs in the management of congestive heart failure (CHF) and atrial fibrillation, many patients presenting to Emergency Departments (EDs) continue to be managed with cardiac glycosides. Cardiotoxicity from cardiac glycosides, known as a class as digitalis, ranges from obvious with nausea, vomiting, and hypotension, to more subtle presentations with nonspecific symptoms. The difficulty in diagnosing patients with digitalis intoxication can be attributed to several factors, including: 1) the signs, symptoms and electrocardiogram (EKG) manifestations often can be attributed to the underlying disease process for which the drug is prescribed; 2) a narrow therapeutic window of digoxin resulting in marked variability in the sensitivity of individuals to the drug; and 3) the lack of any dysrhythmia diagnostic of toxicity 1, 2, 3. It is believed that chronic toxicity occurs in 4–10% of patients on digitalis, yet is suspected in only 0.25% of the cases 4, 5.
Section snippets
Case 1
A 50-year-old man presented to the ED complaining of shortness of breath, nausea, and palpitations. He had a history of atrial fibrillation and congestive heart failure and was taking digoxin. His primary physician had increased his dose of digoxin the week prior from 0.125 mg to 0.25 mg per day because he was having increasing episodes of palpitations.
The patient was a middle-aged man who appeared in moderate distress. Vital signs included a pulse rate of 148 beats/min, blood pressure of 96/52
Discussion
Digitalis derivatives are found in several plants, including oleander, foxglove, and lily of the valley. They are used therapeutically as digoxin or digitoxin primarily for their ability to slow conduction through the atrioventricular (AV) node in disease states such as atrial fibrillation and flutter. These agents act by inhibiting the sodium-potassium adenosine triphosphatase (ATP-ase) pump and increasing intracellular calcium concentration at the level of cardiac myocyte. (6) As a result,
Conclusion
Although digoxin continues to be a common medication utilized by patients presenting to the ED, the nonspecific signs and symptoms make the diagnosis of toxicity difficult to establish. The key to successful management is early diagnosis. Though no single dysrhythmia is always found, certain aberrations such as PAT with block, junctional tachycardia, and bidirectional ventricular tachycardia are common. The hallmark of digitalis toxicity is increased automaticity with concomitant conduction
References (20)
- et al.
Digitalis cardiotoxicity
J Am Coll Cardiol
(1985) Incidence of hospitalization for digitalis toxicity among elderly Americans
Am J Med
(1994)Serum digoxin levels and mortality in 5100 patients
Ann Emerg Med
(1987)Acute and chronic digitalis toxicitypresentation and treatment
Ann Emerg Med
(1982)- et al.
Cardiotoxic drugs
Emerg Med Clin North Am
(1995) - et al.
Mechanism of bidirectional tachycardia
Am Heart J
(1969) - Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992;69:108....
- et al.
Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay
N Engl J Med
(1969) - et al.
Overdose of cardiotoxic drugs
- et al.
Late peaking of the T wave as a digitalis effect
Am Heart J
(1964)
Cited by (96)
Positive Inotropic Drugs for Treating Heart Failure
2022, Comprehensive Pharmacology2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society
2019, Journal of the American College of Cardiology2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
2019, Journal of the American College of CardiologyCardiovascular Toxicity Biomarkers
2019, Biomarkers in Toxicology
- 1
Selected Topics: Cardiology Commentary is coordinated by Theodore Chan, MD, of the University of California San Diego Medical Center, San Diego, California